Anti-β -amyloid immunotherapy for alzheimer's disease: Focus on Bapineuzumab

Francesco Panza, Vincenza Frisardi, Bruno P. Imbimbo, Davide Seripa, Francesco Paris, Andrea Santamato, Grazia D'Onofrio, Giancarlo Logroscino, Alberto Pilotto, Vincenzo Solfrizzi

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Recent advances in our understanding of the neurobiology of Alzheimer's disease (AD) have led to the development of putative disease-modifying treatments. The most revolutionary of these approaches consists in the removal of brain β-amyloid (Aβ) via anti-Aβ antibodies. Brain imaging and neuropathological studies have shown the ability of both active and passive anti-Aβ immunotherapies of clearing Aβ deposits from the brain of the AD patients. An active anti-Aβ vaccine preparation, AN1792, has been used in AD patients with some clues of clinical efficacy but causing meningoencephalitis in about 6% of patients and it has been abandoned. Several second-generation active Aβ vaccines and passive Aβ immunotherapies have been developed and are under clinical investigation with the aim of accelerating Aβ clearance from the brain of the AD patients. The most advanced of these immunological approaches is bapineuzumab, composed of humanized anti-Aβ monoclonal antibodies, that has been tested in two Phase II trials, demonstrating to reduce Aβ burden in the brain of AD patients. However, the preliminary cognitive efficacy of bapineuzumab appears uncertain. The occurrence of vasogenic edema, especially in apolipoprotein E E{open}4 carriers, may limit its clinical use and have led to abandon the highest dose of the drug (2 mg/kg). The results of four ongoing large Phase III trials on bapineuzumab will tell us if passive anti-Aβ immunization is able to alter the course if this devastating disease.

Original languageEnglish
Pages (from-to)808-817
Number of pages10
JournalCurrent Alzheimer Research
Volume8
Issue number8
DOIs
Publication statusPublished - Dec 2011

Fingerprint

Amyloid
Immunotherapy
Alzheimer Disease
Brain Diseases
Vaccines
Meningoencephalitis
Aptitude
Passive Immunization
Neurobiology
Apolipoproteins E
Neuroimaging
Anti-Idiotypic Antibodies
Immunization
Edema
Monoclonal Antibodies
bapineuzumab
Brain
Pharmaceutical Preparations
Therapeutics

Keywords

  • β-amyloid
  • Active immunotherapy
  • Alzheimer's disease
  • Bapineuzumab
  • Passive immunotherapy

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Panza, F., Frisardi, V., Imbimbo, B. P., Seripa, D., Paris, F., Santamato, A., ... Solfrizzi, V. (2011). Anti-β -amyloid immunotherapy for alzheimer's disease: Focus on Bapineuzumab. Current Alzheimer Research, 8(8), 808-817. https://doi.org/10.2174/156720511798192718

Anti-β -amyloid immunotherapy for alzheimer's disease : Focus on Bapineuzumab. / Panza, Francesco; Frisardi, Vincenza; Imbimbo, Bruno P.; Seripa, Davide; Paris, Francesco; Santamato, Andrea; D'Onofrio, Grazia; Logroscino, Giancarlo; Pilotto, Alberto; Solfrizzi, Vincenzo.

In: Current Alzheimer Research, Vol. 8, No. 8, 12.2011, p. 808-817.

Research output: Contribution to journalArticle

Panza, F, Frisardi, V, Imbimbo, BP, Seripa, D, Paris, F, Santamato, A, D'Onofrio, G, Logroscino, G, Pilotto, A & Solfrizzi, V 2011, 'Anti-β -amyloid immunotherapy for alzheimer's disease: Focus on Bapineuzumab', Current Alzheimer Research, vol. 8, no. 8, pp. 808-817. https://doi.org/10.2174/156720511798192718
Panza, Francesco ; Frisardi, Vincenza ; Imbimbo, Bruno P. ; Seripa, Davide ; Paris, Francesco ; Santamato, Andrea ; D'Onofrio, Grazia ; Logroscino, Giancarlo ; Pilotto, Alberto ; Solfrizzi, Vincenzo. / Anti-β -amyloid immunotherapy for alzheimer's disease : Focus on Bapineuzumab. In: Current Alzheimer Research. 2011 ; Vol. 8, No. 8. pp. 808-817.
@article{55e8ddf997d846c88d702124019ce425,
title = "Anti-β -amyloid immunotherapy for alzheimer's disease: Focus on Bapineuzumab",
abstract = "Recent advances in our understanding of the neurobiology of Alzheimer's disease (AD) have led to the development of putative disease-modifying treatments. The most revolutionary of these approaches consists in the removal of brain β-amyloid (Aβ) via anti-Aβ antibodies. Brain imaging and neuropathological studies have shown the ability of both active and passive anti-Aβ immunotherapies of clearing Aβ deposits from the brain of the AD patients. An active anti-Aβ vaccine preparation, AN1792, has been used in AD patients with some clues of clinical efficacy but causing meningoencephalitis in about 6{\%} of patients and it has been abandoned. Several second-generation active Aβ vaccines and passive Aβ immunotherapies have been developed and are under clinical investigation with the aim of accelerating Aβ clearance from the brain of the AD patients. The most advanced of these immunological approaches is bapineuzumab, composed of humanized anti-Aβ monoclonal antibodies, that has been tested in two Phase II trials, demonstrating to reduce Aβ burden in the brain of AD patients. However, the preliminary cognitive efficacy of bapineuzumab appears uncertain. The occurrence of vasogenic edema, especially in apolipoprotein E E{open}4 carriers, may limit its clinical use and have led to abandon the highest dose of the drug (2 mg/kg). The results of four ongoing large Phase III trials on bapineuzumab will tell us if passive anti-Aβ immunization is able to alter the course if this devastating disease.",
keywords = "β-amyloid, Active immunotherapy, Alzheimer's disease, Bapineuzumab, Passive immunotherapy",
author = "Francesco Panza and Vincenza Frisardi and Imbimbo, {Bruno P.} and Davide Seripa and Francesco Paris and Andrea Santamato and Grazia D'Onofrio and Giancarlo Logroscino and Alberto Pilotto and Vincenzo Solfrizzi",
year = "2011",
month = "12",
doi = "10.2174/156720511798192718",
language = "English",
volume = "8",
pages = "808--817",
journal = "Current Alzheimer Research",
issn = "1567-2050",
publisher = "Bentham Science Publishers B.V.",
number = "8",

}

TY - JOUR

T1 - Anti-β -amyloid immunotherapy for alzheimer's disease

T2 - Focus on Bapineuzumab

AU - Panza, Francesco

AU - Frisardi, Vincenza

AU - Imbimbo, Bruno P.

AU - Seripa, Davide

AU - Paris, Francesco

AU - Santamato, Andrea

AU - D'Onofrio, Grazia

AU - Logroscino, Giancarlo

AU - Pilotto, Alberto

AU - Solfrizzi, Vincenzo

PY - 2011/12

Y1 - 2011/12

N2 - Recent advances in our understanding of the neurobiology of Alzheimer's disease (AD) have led to the development of putative disease-modifying treatments. The most revolutionary of these approaches consists in the removal of brain β-amyloid (Aβ) via anti-Aβ antibodies. Brain imaging and neuropathological studies have shown the ability of both active and passive anti-Aβ immunotherapies of clearing Aβ deposits from the brain of the AD patients. An active anti-Aβ vaccine preparation, AN1792, has been used in AD patients with some clues of clinical efficacy but causing meningoencephalitis in about 6% of patients and it has been abandoned. Several second-generation active Aβ vaccines and passive Aβ immunotherapies have been developed and are under clinical investigation with the aim of accelerating Aβ clearance from the brain of the AD patients. The most advanced of these immunological approaches is bapineuzumab, composed of humanized anti-Aβ monoclonal antibodies, that has been tested in two Phase II trials, demonstrating to reduce Aβ burden in the brain of AD patients. However, the preliminary cognitive efficacy of bapineuzumab appears uncertain. The occurrence of vasogenic edema, especially in apolipoprotein E E{open}4 carriers, may limit its clinical use and have led to abandon the highest dose of the drug (2 mg/kg). The results of four ongoing large Phase III trials on bapineuzumab will tell us if passive anti-Aβ immunization is able to alter the course if this devastating disease.

AB - Recent advances in our understanding of the neurobiology of Alzheimer's disease (AD) have led to the development of putative disease-modifying treatments. The most revolutionary of these approaches consists in the removal of brain β-amyloid (Aβ) via anti-Aβ antibodies. Brain imaging and neuropathological studies have shown the ability of both active and passive anti-Aβ immunotherapies of clearing Aβ deposits from the brain of the AD patients. An active anti-Aβ vaccine preparation, AN1792, has been used in AD patients with some clues of clinical efficacy but causing meningoencephalitis in about 6% of patients and it has been abandoned. Several second-generation active Aβ vaccines and passive Aβ immunotherapies have been developed and are under clinical investigation with the aim of accelerating Aβ clearance from the brain of the AD patients. The most advanced of these immunological approaches is bapineuzumab, composed of humanized anti-Aβ monoclonal antibodies, that has been tested in two Phase II trials, demonstrating to reduce Aβ burden in the brain of AD patients. However, the preliminary cognitive efficacy of bapineuzumab appears uncertain. The occurrence of vasogenic edema, especially in apolipoprotein E E{open}4 carriers, may limit its clinical use and have led to abandon the highest dose of the drug (2 mg/kg). The results of four ongoing large Phase III trials on bapineuzumab will tell us if passive anti-Aβ immunization is able to alter the course if this devastating disease.

KW - β-amyloid

KW - Active immunotherapy

KW - Alzheimer's disease

KW - Bapineuzumab

KW - Passive immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=80053385682&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053385682&partnerID=8YFLogxK

U2 - 10.2174/156720511798192718

DO - 10.2174/156720511798192718

M3 - Article

C2 - 21592055

AN - SCOPUS:80053385682

VL - 8

SP - 808

EP - 817

JO - Current Alzheimer Research

JF - Current Alzheimer Research

SN - 1567-2050

IS - 8

ER -